Literature DB >> 23907202

FDG-PET may predict the effectiveness of hyperbaric oxygen therapy in a patient with bisphosphonate-related osteonecrosis of the jaw: report of a case.

Chowdhury Nusrat Fatema1, Jun Sato, Yutaka Yamazaki, Hironobu Hata, Naoya Hattori, Tohru Shiga, Nagara Tamaki, Yoshimasa Kitagawa.   

Abstract

We report an advanced case of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in an osteoporotic patient treated with oral risedronate sodium for 2 years. An 80-year-old woman presented to our hospital complaining of pain, swelling and pus discharge in the lower alveolar ridge. Fluorine-18 labeled fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scintigraphy showed definite uptake in the mandible. Under clinical diagnosis of BRONJ, we applied systematic treatments including antibiotic therapy, irrigation, cessation of bisphosphonate, hyperbaric oxygen (HBO) therapy, and debridement of necrotic bone. After pre-operative 20 sessions of HBO therapy, her clinical symptoms disappeared. SUVmax of FDG-PET decreased definitely from 4.5 to 2.5, although magnetic resonance image and bone scintigraphy did not show remarkable changes. After minor surgery with debridement of necrotic bone, she received another ten sessions of HBO therapy. After the treatment, her clinical course was excellent. In conclusion, this report demonstrates FDG-PET may predict the effect of HBO therapy in BRONJ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907202     DOI: 10.1007/s10266-013-0129-y

Source DB:  PubMed          Journal:  Odontology        ISSN: 1618-1247            Impact factor:   2.634


  10 in total

1.  Use of FDG PET to evaluate hyperbaric oxygen therapy for bisphosphonate-related osteonecrosis of the jaw.

Authors:  Yutaka Yamazaki; Yoshimasa Kitagawa; Hironobu Hata; Takahiro Abe; Chika Murai; Tohru Shiga; Nagara Tamaki
Journal:  Clin Nucl Med       Date:  2010-08       Impact factor: 7.794

2.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

Authors: 
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

3.  Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.

Authors:  Michele D Mignogna; Stefano Fedele; Lucio Lo Russo; Roberto Ciccarelli; Lorenzo Lo Muzio
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

4.  A new concept in the treatment of osteoradionecrosis.

Authors:  R E Marx
Journal:  J Oral Maxillofac Surg       Date:  1983-06       Impact factor: 1.895

5.  Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.

Authors:  E Nastro; C Musolino; A Allegra; G Oteri; M Cicciù; A Alonci; E Quartarone; C Alati; F S De Ponte
Journal:  Acta Haematol       Date:  2006-12-12       Impact factor: 2.195

6.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

7.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

Review 8.  Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.

Authors:  John J Freiberger
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

9.  Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study.

Authors:  Joseph V Boykin; Chris Baylis
Journal:  Adv Skin Wound Care       Date:  2007-07       Impact factor: 2.347

Review 10.  A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach.

Authors:  J J Feldmeier; N B Hampson
Journal:  Undersea Hyperb Med       Date:  2002       Impact factor: 0.698

  10 in total
  4 in total

1.  The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.

Authors:  Olga Di Fede; Federica Canepa; Vera Panzarella; Rodolfo Mauceri; Carmine Del Gaizo; Alberto Bedogni; Vittorio Fusco; Pietro Tozzo; Giuseppe Pizzo; Giuseppina Campisi; Antonio Galvano
Journal:  Int J Environ Res Public Health       Date:  2021-08-10       Impact factor: 3.390

Review 2.  Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw.

Authors:  Yoshimasa Kitagawa; Noritaka Ohga; Takuya Asaka; Jun Sato; Hironobu Hata; Joseph Helman; Kanako Tsuboi; Norio Amizuka; Yuji Kuge; Tohru Shiga
Journal:  Jpn Dent Sci Rev       Date:  2019-03-15

3.  Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.

Authors:  Takuma Watanabe; Keita Asai; Shizuko Fukuhara; Ryuji Uozumi; Kazuhisa Bessho
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

Review 4.  Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication).

Authors:  Makoto Tsuchimochi; Tohru Kurabayashi
Journal:  Jpn Dent Sci Rev       Date:  2019-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.